Avenue Therapeutics to Participate in Upcoming Investor Conferences

Core Viewpoint - Avenue Therapeutics, Inc. is actively engaging with investors through participation in upcoming conferences, highlighting its focus on therapies for neurologic diseases [1][2]. Group 1: Upcoming Conferences - Avenue Therapeutics will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, in New York, featuring a company presentation and one-on-one meetings [1]. - The company will also attend the Lake Street Capital Markets BIG8 Conference on September 12, 2024, in New York, which will consist of one-on-one meetings [1]. - The H.C. Wainwright company presentation will be available for on-demand viewing starting September 9, 2024, at 7:00 a.m. ET [1]. Group 2: Company Overview - Avenue Therapeutics is a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic diseases [2]. - The company is currently developing three key assets: AJ201 for spinal and bulbar muscular atrophy, BAER-101 as a selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for managing acute postoperative pain in adults [2]. - Avenue Therapeutics is headquartered in Miami, FL, and was founded by Fortress Biotech, Inc. [2].